Interleukin-15 plays a central role in human kidney physiology and cancer through the γc signaling pathway

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Giron Michel, Julien ^a,b   Azzi, Sandy ^a,b   Khawam, Krystel ^a,b   Mortier, Erwan ^c   Caignard, Anne ^d   Devocelle, Aurore ^a,b   Ferrini, Silvano ^e   Croce, Michela ^e   François, Hélène ^a,b   Lecru, Lola ^a,b   Charpentier, Bernard ^a,b   Chouaib, Salem ^f   Azzarone, Bruno ^a,b   Eid, Pierre ^a,b  

^a HÔPITAL PAUL BROUSSE   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d INSTITUT COCHIN   (France)

^e UNIVERSITY OF GENOA   (Italy)

^f INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HETERODIMER; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR; INTERLEUKIN 15 RECEPTOR GAMMA; JANUS KINASE 3; STAT5 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; IL15 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR GAMMA;

ARTICLE; CANCER INHIBITION; CELL SURVIVAL; COMPLEX FORMATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENETIC TRANSFECTION; HOMEOSTASIS AND REGULATION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SUBUNIT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; CELL LINE; DRUG EFFECT; EPITHELIUM CELL; IMMUNOHISTOCHEMISTRY; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SOLUBILITY; UPREGULATION;

CADHERINS; CARCINOMA, RENAL CELL; CELL LINE; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; INTERLEUKIN-15; KIDNEY NEOPLASMS; KIDNEY TUBULES, PROXIMAL; SIGNAL TRANSDUCTION; SOLUBILITY; UP-REGULATION;

EID: 84857395797     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031624     Document Type: Article

References (59)

1. Budagian V, Bulanova E, Paus R, Bulfone-Paus S, (2006) IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev 17: 259-280.
2. Waldmann TA, (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6: 595-601.
3. Anderson DM, Kumaki S, Ahdieh M, Bertles J, Tometsko M, et al. (1995) Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J Biol Chem 270: 29862-29869.
4. Giri JG, Ahdieh M, Eisenman J, Shanebeck K, Grabstein K, et al. (1994) Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J 13: 2822-2830.
5. Atzpodien J, Lopez Hanninen E, Kirchner H, Bodenstein H, Pfreundschuh M, et al. (1995) Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol 13: 497-501.
6. de Totero D, Meazza R, Capaia M, Fabbi M, Azzarone B, et al. (2008) The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 111: 517-524.
7. Ghoreschi K, Laurence A, O'Shea JJ, (2009) Janus kinases in immune cell signaling. Immunol Rev 228: 273-287.
8. Rochman Y, Spolski R, Leonard WJ, (2009) New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 9: 480-490.
9. Amorosi S, Russo I, Amodio G, Garbi C, Vitiello L, et al. (2009) The cellular amount of the common gamma-chain influences spontaneous or induced cell proliferation. Journal of immunology 182: 3304-3309.
10. Kovanen PE, Leonard WJ, (2004) Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 202: 67-83.
11. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM, (2006) Gene therapy: therapeutic gene causing lymphoma. Nature 440: 1123.
12. Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, et al. (2004) Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res 6: R1-7.
13. Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, et al. (2003) Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res 9: 4802-4810.
14. Reichert TE, Nagashima S, Kashii Y, Stanson J, Gao G, et al. (2000) Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 19: 514-525.
15. Tejman-Yarden N, Zlotnik M, Lewis E, Etzion O, Chaimovitz C, et al. (2005) Renal cells express a functional interleukin-15 receptor. Nephrol Dial Transplant 20: 516-523.
16. Tsukadaira A, Okubo Y, Koyama S, Sato E, Nagase H, et al. (2002) Human bronchial epithelium expresses interleukin-9 receptors and releases neutrophil chemotactic factor. Exp Lung Res 28: 123-139.
17. Di Sabatino A, Ciccocioppo R, Cupelli F, Cinque B, Millimaggi D, et al. (2006) Epithelium derived interleukin 15 regulates intraepithelial lymphocyte Th1 cytokine production, cytotoxicity, and survival in coeliac disease. Gut 55: 469-477.
18. Ge N, Nishioka Y, Nakamura Y, Okano Y, Yoneda K, et al. (2004) Synthesis and secretion of interleukin-15 by freshly isolated human bronchial epithelial cells. Int Arch Allergy Immunol 135: 235-242.
19. Obermeier F, Hausmann M, Kellermeier S, Kiessling S, Strauch UG, et al. (2006) IL-15 protects intestinal epithelial cells. Eur J Immunol 36: 2691-2699.
20. Shinozaki M, Hirahashi J, Lebedeva T, Liew FY, Salant DJ, et al. (2002) IL-15, a survival factor for kidney epithelial cells, counteracts apoptosis and inflammation during nephritis. J Clin Invest 109: 951-960.
21. Weiler M, Rogashev B, Einbinder T, Hausmann MJ, Kaneti J, et al. (1998) Interleukin-15, a leukocyte activator and growth factor, is produced by cortical tubular epithelial cells. J Am Soc Nephrol 9: 1194-1201.
22. Eini H, Tejman-Yarden N, Lewis EC, Chaimovitz C, Zlotnik M, et al. (2009) Association between renal injury and reduced interleukin-15 and interleukin-15 receptor levels in acute kidney injury. J Interferon Cytokine Res 30: 1-8.
23. Nishiyama R, Sakaguchi T, Kinugasa T, Gu X, MacDermott RP, et al. (2001) Interleukin-2 receptor beta subunit-dependent and-independent regulation of intestinal epithelial tight junctions. J Biol Chem 276: 35571-35580.
24. Maiuri L, Ciacci C, Auricchio S, Brown V, Quaratino S, et al. (2000) Interleukin 15 mediates epithelial changes in celiac disease. Gastroenterology 119: 996-1006.
25. Reinecker HC, MacDermott RP, Mirau S, Dignass A, Podolsky DK, (1996) Intestinal epithelial cells both express and respond to interleukin 15. Gastroenterology 111: 1706-1713.
26. Yanagita M, Shimabukuro Y, Nozaki T, Yoshimura N, Watanabe J, et al. (2002) IL-15 up-regulates iNOS expression and NO production by gingival epithelial cells. Biochem Biophys Res Commun 297: 329-334.
27. Viey E, Laplace C, Escudier B, (2005) Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert Rev Anticancer Ther 5: 973-986.
28. Giron-Michel J, Giuliani M, Fogli M, Brouty-Boye D, Ferrini S, et al. (2005) Membrane-bound and soluble IL-15/IL-15Ralpha complexes display differential signaling and functions on human hematopoietic progenitors. Blood 106: 2302-2310.
29. Khawam K, Giron-Michel J, Gu Y, Perier A, Giuliani M, et al. (2009) Human renal cancer cells express a novel membrane-bound interleukin-15 that induces, in response to the soluble interleukin-15 receptor alpha chain, epithelial-to-mesenchymal transition. Cancer Res 69: 1561-1569.
30. Mortier E, Bernard J, Plet A, Jacques Y, (2004) Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 173: 1681-1688.
31. Bussolati B, Bruno S, Grange C, Ferrando U, Camussi G, (2008) Identification of a tumor-initiating stem cell population in human renal carcinomas. FASEB J 22: 3696-3705.
32. Giron-Michel J, Menard F, Negrini S, Devocelle A, Azzarone B, et al. (2009) EBV-associated mononucleosis does not induce long-term global deficit in T-cell responsiveness to IL-15. Blood 113: 4541-4547.
33. Hofmann SR, Lam AQ, Frank S, Zhou YJ, Ramos HL, et al. (2004) Jak3-independent trafficking of the common gamma chain receptor subunit: chaperone function of Jaks revisited. Mol Cell Biol 24: 5039-5049.
34. Cortes JR, Perez GM, Rivas MD, Zamorano J, (2007) Kaempferol inhibits IL-4-induced STAT6 activation by specifically targeting JAK3. J Immunol 179: 3881-3887.
35. Musso T, Johnston JA, Linnekin D, Varesio L, Rowe TK, et al. (1995) Regulation of JAK3 expression in human monocytes: phosphorylation in response to interleukins 2, 4, and 7. J Exp Med 181: 1425-1431.
36. Stone KP, Kastin AJ, Hsuchou H, Yu C, Pan W, (2011) Rapid endocytosis of interleukin-15 by cerebral endothelia. J Neurochem 116: 544-553.
37. van Roy F, Berx G, (2008) The cell-cell adhesion molecule E-cadherin. Cell Mol Life Sci 65: 3756-3788.
38. Sasson R, Amsterdam A, (2003) Pleiotropic anti-apoptotic activity of glucocorticoids in ovarian follicular cells. Biochem Pharmacol 66: 1393-1401.
39. Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, et al. (2010) ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene 29: 3490-3500.
40. Wells A, Yates C, Shepard CR, (2008) E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis 25: 621-628.
41. Zheng G, Lyons JG, Tan TK, Wang Y, Hsu TT, et al. (2009) Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesenchymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol 175: 580-591.
42. Fiorito S, Magrini L, Adrey J, Mailhe D, Brouty-Boye D, (2005) Inflammatory status and cartilage regenerative potential of synovial fibroblasts from patients with osteoarthritis and chondropathy. Rheumatology (Oxford) 44: 164-171.
43. Jakobisiak M, Golab J, Lasek W, (2011) Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev 22: 99-108.
44. Wong WK, Robertson H, Carroll HP, Ali S, Kirby JA, (2003) Tubulitis in renal allograft rejection: role of transforming growth factor-beta and interleukin-15 in development and maintenance of CD103+ intraepithelial T cells. Transplantation 75: 505-514.
45. Yabu JM, Vincenti F, (2007) Novel immunosuppression: small molecules and biologics. Semin Nephrol 27: 479-486.
46. Ogbomo H, Michaelis M, Altenbrandt B, Doerr HW, Cinatl J Jr, (2010) A novel immunomodulatory mechanism of ribavirin in suppressing natural killer cell function. Biochem Pharmacol 79: 188-197.
47. Lai KS, Jin Y, Graham DK, Witthuhn BA, Ihle JN, et al. (1995) A kinase-deficient splice variant of the human JAK3 is expressed in hematopoietic and epithelial cancer cells. J Biol Chem 270: 25028-25036.
48. Damiano L, Di Stefano P, Camacho Leal MP, Barba M, Mainiero F, et al. (2010) p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation. Oncogene 29: 3677-3690.
49. Davies M, Robinson M, Smith E, Huntley S, Prime S, et al. (2005) Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. Journal of cellular biochemistry 95: 918-931.
50. Gambaro G, Abaterusso C, (2007) Pathophysiology of hypercalciuria. American journal of physiology Renal physiology 293: F1758; author reply F1759.
51. Hamada S, Satoh K, Hirota M, Kimura K, Kanno A, et al. (2007) Bone morphogenetic protein 4 induces epithelial-mesenchymal transition through MSX2 induction on pancreatic cancer cell line. Journal of cellular physiology 213: 768-774.
52. Xu G, Liu A, Liu X, (2008) Aldosterone induces collagen synthesis via activation of extracellular signal-regulated kinase 1 and 2 in renal proximal tubules. Nephrology 13: 694-701.
53. Zhang G, Kernan KA, Collins SJ, Cai X, Lopez-Guisa JM, et al. (2007) Plasmin(ogen) promotes renal interstitial fibrosis by promoting epithelial-to-mesenchymal transition: role of plasmin-activated signals. Journal of the American Society of Nephrology: JASN 18: 846-859.
54. Peinado H, Portillo F, Cano A, (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48: 365-375.
55. Notarangelo LD, Giliani S, Mella P, Schumacher RF, Mazza C, et al. (2000) Combined immunodeficiencies due to defects in signal transduction: defects of the gammac-JAK3 signaling pathway as a model. Immunobiology 202: 106-119.
56. Bosco MC, Espinoza-Delgado I, Schwabe M, Gusella GL, Longo DL, et al. (1994) Regulation by interleukin-2 (IL-2) and interferon gamma of IL-2 receptor gamma chain gene expression in human monocytes. Blood 83: 2995-3002.
57. Han Y, Amin HM, Franko B, Frantz C, Shi X, et al. (2006) Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma. Blood 108: 2796-2803.
58. Franciszkiewicz K, Le Floc'h A, Jalil A, Vigant F, Robert T, et al. (2009) Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res 69: 6249-6255.
59. Le Floc'h A, Jalil A, Vergnon I, Le Maux Chansac B, Lazar V, et al. (2007) Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med 204: 559-570.